Collectively, these findings show that delphinidin may play a chemotherapeutic role in ovarian cancer cell prevention and progression by inactivating PI3K/Akt and ERK1/2 MAPK signaling pathways. The gene discussed is AKT1; the disease is ovarian carcinoma.